Full Press Release Details
Novel Approaches to Hearing Restoration Corporate Overview September 2021 Copyright Frequency Therapeutics, Inc. 1Exhibit 99.1 LEADING A NEW CATEGORY IN REGENERATIVE MEDICINE Advancing Novel Approaches to Hearing Restoration Corporate Overview
September 2021 Copyright Frequency Therapeutics, Inc. 1
Forward-Looking Statements and Other Disclaimers This presentation
contains forward-looking statements within the meaning of the to maintain Fast Track designation for FX-322 and such designation failing to result Private Securities Litigation Reform Act of 1995. All statements contained in this in faster
development or regulatory review or approval; costly and damaging presentation that do not relate to matters of historical fact should be considered litigation, including related to product liability, intellectual property or brought by
forward-looking statements, including without limitation statements regarding the stockholders; dependence on Astellas Pharma Inc. for the development and interpretation and implications of the results of the Phase 2a study as well as the
commercialization of FX-322 outside of the United States; misconduct by FX-322-112 and the FX-322-111 studies, the timing and results of top-line data employees or independent contractors; reliance on third parties, including to from the Phase 1b
study in severe SNHL, the initiation, timing and design of the conduct clinical trials and manufacture product candidates; compliance with laws new Phase 2 trial of FX-322, including the ability of study design to address study and regulations,
including healthcare and environmental, health, and safety laws bias, the design and timing of future studies of and clinical development path for and regulations; failure to obtain, maintain and enforce protection of patents and FX-322, the results
and implications of the Phase 1/2 durability of response data, other intellectual property; security breaches or failure to protect private personal the ability of our technology platform to provide patient benefit, the impact of information;
attracting and retaining key personnel; and ability to manage growth. COVID-19 on the Company's on-going and planned clinical trials and business, future milestone and royalty payments under the license and collaboration These and other
important factors discussed under the caption "Risk factors" in the agreement with Astellas Pharma Inc. ("Astellas"), the sufficiency of the Company's Company's Form 10-Q filed with the Securities and Exchange
Commission (SEC) on cash, cash equivalents and short-term investments, estimates of the size of the August 12, 2021 and its other reports filed with the SEC could cause actual results hearing loss population and population at risk for hearing loss,
estimates of the to differ materially from those indicated by the forward-looking statements made commercial opportunity of FX-322 and the impact on existing treatment in this presentation. Any such forward-looking statements represent
management's paradigms, the timing and progress of the remyelination program, and the estimates as of the date of this presentation. While the Company may elect to potential application of the PCA platform to other diseases. update such
forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These These forward-looking statements are based on management's current forward-looking
statements should not be relied upon as representing the expectations. These statements are neither promises nor guarantees, but involve Company's views as of any date subsequent to the date of this presentation. known and unknown risks,
uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including,
but not limited to, the following: the impact of COVID-19 on the Company's ongoing and planned clinical trials, research and development and manufacturing activities, the relocation of the Company's offices and laboratory facilities, the
Company's business and financial markets; Frequency Therapeutics (the "Company") has incurred and will continue to incur significant losses and is not and may never be profitable; need for additional funding to complete development
and commercialization of any product candidate; the Company's dependence on the development of FX-322; the unproven approach of the PCA platform; the lengthy, expensive and uncertain process of clinical drug development and regulatory
approval; limited experience successfully obtaining marketing approval for and commercializing product candidates; the results of earlier clinical trials not being indicative of the results from later clinical trials; differences between preliminary
or interim data and final data; adverse events or undesirable side effects; disruptions at the FDA and other regulatory agencies; failure to identify additional product candidates; new or changed legislation; failure c Frequency Therapeutics, Inc.
2Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within the meaning of the to maintain Fast Track designation for FX-322 and such designation failing to result Private Securities Litigation
Reform Act of 1995. All statements contained in this in faster development or regulatory review or approval; costly and damaging presentation that do not relate to matters of historical fact should be considered litigation, including related to
product liability, intellectual property or brought by forward-looking statements, including without limitation statements regarding the stockholders; dependence on Astellas Pharma Inc. for the development and interpretation and implications of the
results of the Phase 2a study as well as the commercialization of FX-322 outside of the United States; misconduct by FX-322-112 and the FX-322-111 studies, the timing and results of top-line data employees or independent contractors; reliance on
third parties, including to from the Phase 1b study in severe SNHL, the initiation, timing and design of the conduct clinical trials and manufacture product candidates; compliance with laws new Phase 2 trial of FX-322, including the ability of study
design to address study and regulations, including healthcare and environmental, health, and safety laws bias, the design and timing of future studies of and clinical development path for and regulations; failure to obtain, maintain and enforce
protection of patents and FX-322, the results and implications of the Phase 1/2 durability of response data, other intellectual property; security breaches or failure to protect private personal the ability of our technology platform to provide
patient benefit, the impact of information; attracting and retaining key personnel; and ability to manage growth. COVID-19 on the Company's on-going and planned clinical trials and business, future milestone and royalty payments under the
license and collaboration These and other important factors discussed under the caption "Risk factors" in the agreement with Astellas Pharma Inc. ("Astellas"), the sufficiency of the Company's Company's Form 10-Q
filed with the Securities and Exchange Commission (SEC) on cash, cash equivalents and short-term investments, estimates of the size of the August 12, 2021 and its other reports filed with the SEC could cause actual results hearing loss population
and population at risk for hearing loss, estimates of the to differ materially from those indicated by the forward-looking statements made commercial opportunity of FX-322 and the impact on existing treatment in this presentation. Any such
forward-looking statements represent management's paradigms, the timing and progress of the remyelination program, and the estimates as of the date of this presentation. While the Company may elect to potential application of the PCA platform
to other diseases. update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These These forward-looking statements are based on management's
current forward-looking statements should not be relied upon as representing the expectations. These statements are neither promises nor guarantees, but involve Company's views as of any date subsequent to the date of this presentation. known
and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking
statements, including, but not limited to, the following: the impact of COVID-19 on the Company's ongoing and planned clinical trials, research and development and manufacturing activities, the relocation of the Company's offices and
laboratory facilities, the Company's business and financial markets; Frequency Therapeutics (the "Company") has incurred and will continue to incur significant losses and is not and may never be profitable; need for additional
funding to complete development and commercialization of any product candidate; the Company's dependence on the development of FX-322; the unproven approach of the PCA platform; the lengthy, expensive and uncertain process of clinical drug
development and regulatory approval; limited experience successfully obtaining marketing approval for and commercializing product candidates; the results of earlier clinical trials not being indicative of the results from later clinical trials;
differences between preliminary or interim data and final data; adverse events or undesirable side effects; disruptions at the FDA and other regulatory agencies; failure to identify additional product candidates; new or changed legislation; failure
c Frequency Therapeutics, Inc. 2
Frequency Today: Guided by a Clear Signal First ever known clinical
studies Leading the field of demonstrating hearing restoration hearing improvements c Frequency Therapeutics, Inc. 3 Copyright Frequency Therapeutics, Inc. 3Frequency Today: Guided by a Clear Signal First ever known clinical studies Leading the
field of demonstrating hearing restoration hearing improvements c Frequency Therapeutics, Inc. 3 Copyright Frequency Therapeutics, Inc. 3
Defining the Target, Expanding the Pipeline Learnings from Working to
expand our exploratory studies pipeline for hearing support new Phase 2 therapeutics and for trial and help define other degenerative path forward diseases c Frequency Therapeutics, Inc. 4 Copyright Frequency Therapeutics, Inc. 4Defining the Target,
Expanding the Pipeline Learnings from Working to expand our exploratory studies pipeline for hearing support new Phase 2 therapeutics and for trial and help define other degenerative path forward diseases c Frequency Therapeutics, Inc. 4 Copyright
Frequency Therapeutics, Inc. 4
Today's Hearing Loss Market Has No Restorative Treatments Only 20%
~$10 Billion ~41 Million $980 Billion Lost annually due market US hearing aid Individuals to untreated penetration for market annual with SNHL in hearing loss hearing aids sales U.S. globally* *Source: World Health Organization c Frequency
Therapeutics, Inc. 5Today's Hearing Loss Market Has No Restorative Treatments Only 20% ~$10 Billion ~41 Million $980 Billion Lost annually due market US hearing aid Individuals to untreated penetration for market annual with SNHL in hearing
loss hearing aids sales U.S. globally* *Source: World Health Organization c Frequency Therapeutics, Inc. 5
Intelligibility of Speech and Sound - A Major Unmet Clinical Need People
with hearing loss don't just want their hearing improved, they want hearing restoredIntelligibility of Speech and Sound - A Major Unmet Clinical Need People with hearing loss don't just want their hearing improved, they want hearing
Hearing Loss Can Have a Significant Impact on Overall Health Increased
risks with untreated hearing loss "Hearing loss is the largest potentially modifiable risk factor for developing 50% 41% dementia" July, 2020 DEMENTIA DEPRESSION JAMA Nov 8, 2018 Deal J, et al. Incident Hearing Loss and Comorbidity. A
Longitudinal CO OP 2021 Administrative Claims Study.Hearing Loss Can Have a Significant Impact on Overall Health Increased risks with untreated hearing loss "Hearing loss is the largest potentially modifiable risk factor for developing
50% 41% dementia" July, 2020 DEMENTIA DEPRESSION JAMA Nov 8, 2018 Deal J, et al. Incident Hearing Loss and Comorbidity. A Longitudinal CO OP 2021 Administrative Claims Study.
Frequency Therapeutics: A Vision Built on Regeneration Since 2014,
Frequency has focused on developing therapeutics by activating a person's innate regenerative potential, within the body, to repair tissue and restore human function. c Frequency Therapeutics, Inc. 8Frequency Therapeutics: A Vision Built on
Regeneration Since 2014, Frequency has focused on developing therapeutics by activating a person's innate regenerative potential, within the body, to repair tissue and restore human function. c Frequency Therapeutics, Inc. 8
The Problem: Missing Sensory Hair Cells in the Cochlea Missing Sensory
Hair Cells "Analysis of hair cells, auditory nerve fibers and strial tissues shows that the degree of hearing loss is well predicted from the amount of hair cell loss." - Journal of Neuroscience Sensory Hair Cells July 2020
Progenitor Cells 9The Problem: Missing Sensory Hair Cells in the Cochlea Missing Sensory Hair Cells "Analysis of hair cells, auditory nerve fibers and strial tissues shows that the degree of hearing loss is well predicted from the
amount of hair cell loss." - Journal of Neuroscience Sensory Hair Cells July 2020 Progenitor Cells 9
Solution: A Therapy to Address the Underlying Pathology Synergy between
pathways aims to activate progenitor cells and regenerate sensory cells in the cochlea 10Solution: A Therapy to Address the Underlying Pathology Synergy between pathways aims to activate progenitor cells and regenerate sensory cells in the cochlea
FX-322: Directly Targeting the Regeneration of Sensory Hair Cells in
the Cochlea FX-322 is administered via a standard The injection concentrates FX-322 in intratympanic injection, a routine procedure the cochlear region critical for performed by ENTs speech intelligibility c Frequency Therapeutics, Inc. 11FX-322:
Directly Targeting the Regeneration of Sensory Hair Cells in the Cochlea FX-322 is administered via a standard The injection concentrates FX-322 in intratympanic injection, a routine procedure the cochlear region critical for performed by ENTs
speech intelligibility c Frequency Therapeutics, Inc. 11
Increasing Focus on Hearing Clarity Intelligibility (Clarity)
Audibility (Loudness) measured with word recognition and measured with pure tone words-in-noise tests test "When you develop SNHL, the issue is not just that you can't hear soft sounds. That's why if Word Recognition Test you ever talked to
anyone who List of 50 monosyllabic words has a hearing loss, what they'll Single words played in quiet say is it's not that I can't hear you it's I can't understand you." Words-in-Noise Test - Dr. Frank Lin from
Externally-Led Patient Focused Drug Development program on Background noise from SNHL, June 2021 multiple voices Played at different signal-to-noise ratios c Frequency Therapeutics, Inc. 12Increasing Focus on Hearing Clarity
Intelligibility (Clarity) Audibility (Loudness) measured with word recognition and measured with pure tone words-in-noise tests test "When you develop SNHL, the issue is not just that you can't hear soft sounds. That's why if Word Recognition
Test you ever talked to anyone who List of 50 monosyllabic words has a hearing loss, what they'll Single words played in quiet say is it's not that I can't hear you it's I can't understand you." Words-in-Noise Test - Dr.
Frank Lin from Externally-Led Patient Focused Drug Development program on Background noise from SNHL, June 2021 multiple voices Played at different signal-to-noise ratios c Frequency Therapeutics, Inc. 12
Two Independent Studies (FX-322-201, FX-322-111) Show Hearing
Improvements with Single Dose Day 90 Word Recognition Scores Across Studies Phase 1/2 Study FX-322-201 Phase 1b Study FX-322-111 FX-322-201 Phase 1/2 FX-322-111 Phase 1b Overview Overview 40% Placebo-controlled, multi-center,
Compared different FX-322 % Exceeding Absolute 10% randomized study administration conditions Mild to moderately severe subjects, age Open-label, multi-center, 18-65 (n=23) randomized study 30% NIHL/SSNHL Mild to
severe subjects, age 18- 65 (n=33) 20% Study Results Study Results 33% of subjects achieved 10% or 34% of subjects achieved 10% or greater greater absolute improvement in word absolute improvement in word recognition 10% recognition
in treated ear (WR) in treated ear Statistically significant and clinically Statistically significant and clinically meaningful improvements in WR meaningful improvements in WR No meaningful changes in Favorable
safety profile 0% placebo group Placebo FX-322 Untreated* FX-322 * *Total of 33 patients enrolled in study, Favorable safety profile (n=8) (n=15) (n=32) (n=32) 32 subjects completed 90-day clinical assessment period 13Two Independent Studies
(FX-322-201, FX-322-111) Show Hearing Improvements with Single Dose Day 90 Word Recognition Scores Across Studies Phase 1/2 Study FX-322-201 Phase 1b Study FX-322-111 FX-322-201 Phase 1/2 FX-322-111 Phase 1b Overview Overview 40%
Placebo-controlled, multi-center, Compared different FX-322 % Exceeding Absolute 10% randomized study administration conditions Mild to moderately severe subjects, age Open-label, multi-center, 18-65 (n=23) randomized study
30% NIHL/SSNHL Mild to severe subjects, age 18- 65 (n=33) 20% Study Results Study Results 33% of subjects achieved 10% or 34% of subjects achieved 10% or greater greater absolute improvement in word absolute
improvement in word recognition 10% recognition in treated ear (WR) in treated ear Statistically significant and clinically Statistically significant and clinically meaningful improvements in WR meaningful improvements in WR
No meaningful changes in Favorable safety profile 0% placebo group Placebo FX-322 Untreated* FX-322 * *Total of 33 patients enrolled in study, Favorable safety profile (n=8) (n=15) (n=32) (n=32) 32 subjects completed 90-day clinical
assessment period 13
FX-322 Phase 1/2 Durability Data: Patients Show Sustained Hearing
Improvements 13-21 Months After Initial Dosing 50 50W Month 16** Month 21** Month 21** Month 19** Month 13** 47 Key Findings 50W 50W 40 *25W 39 38 38 50W Preliminary evidence indicating a 50W 35 durable benefit of hearing clarity 34 *25W 50W 30 30
29 50W Baseline - Correct words out of 50 26 50W 50W Day 90 - Correct words out of 50 22 20 20 1-2 Years - Correct words out of 50 50W 50W 16 50W 14 Three patients who had durable improvements 12 10 in intelligibility also had pure tone audiometry
50W improvements of 10 - 15 dB at the highest 7 frequency tested (8k Hz) 0 Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 *25W = 25 Word test performed outside an official study site at 13-18 months after dosing; results scaled to
50 words 50W = 50 Word test performed under a formal protocol at original study site at 18-21 months after dosing c Frequency Therapeutics, Inc. 14 **Since FX-322 dosingFX-322 Phase 1/2 Durability Data: Patients Show Sustained
Hearing Improvements 13-21 Months After Initial Dosing 50 50W Month 16** Month 21** Month 21** Month 19** Month 13** 47 Key Findings 50W 50W 40 *25W 39 38 38 50W Preliminary evidence indicating a 50W 35 durable benefit of hearing clarity 34 *25W 50W
30 30 29 50W Baseline - Correct words out of 50 26 50W 50W Day 90 - Correct words out of 50 22 20 20 1-2 Years - Correct words out of 50 50W 50W 16 50W 14 Three patients who had durable improvements 12 10 in intelligibility also had pure tone